Antihyperlipidemic effect of peucedanum pastinacifolium extract in streptozotocin-induced diabetic rats by Movahedian, Ahmad et al.
CLINICS 2010;65(6):629-33
Copyright © 2010 CLINICS – This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.
org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
BASIC RESEARCH
I
 Department of Clinical Biochemistry, Isfahan Pharmaceutical Sciences 
Research Center, School of Pharmacy and Pharmaceutical Sciences, Isfahan 
University of Medical Sciences, Isfahan, Iran.
II Department of Pharmacognosy, School of Pharmacy and Pharmaceutical 
Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
Tel.: 983117922593
E-mail: zolfaghari@pharm.mui.ac.ir
Received for publication on
First review completed on
Accepted for publication on
ANTIHYPERLIPIDEMIC EFFECT OF PEUCEDANUM PASTINACIFOLIUM EXTRACT IN 
STREPTOZOTOCIN-INDUCED DIABETIC RATS
Ahmad Movahedian,I Behzad Zolfaghari,II S.Ebrahim Sajjadi, II Reza MoknatjouI 
 
doi: 10.1590/S1807-59322010000600011
Movahedian A, Zolfaghari B, Sajjadi SE, Moknatjou R. Antihyperlipidemic effect of peucedanum pastinacifolium extract in 
streptozotocin-induced diabetic rats. Clinics. 2010;65(6):629-33.
INTRODUCTION: Dyslipidemia is one of the most common complications of diabetes mellitus, significantly contributing to 
cardiovascular morbidity and mortality in diabetic patients. Peucedanum pastinacifolium Boiss. & Hausskn. is commonly used 
as an antihyperlipidemic vegetable in Iranian folk medicine. MATERIAL AND METHODS: In this study, we examined a 
hydroalcoholic extract of the aerial parts of Peucedanum pastinacifolium to determine its lipid-lowering activity in normal and 
streptozotocin (STZ)-induced diabetic rats. Experimental diabetes mellitus was induced by a single intraperitoneal administration 
of streptozotocin. Normal and streptozotocin-induced diabetic rats were separated into four groups. The groups were fed with 0, 
125, 250 or 500 mg/kg body weight of Peucedanum Pastinacifolium hydroalcoholic Extract (PPE) in aqueous solution for 30 days. 
RESULTS: The results show that there were significant (P < 0.05) increases in total serum cholesterol, triglyceride and low-density 
lipoprotein cholesterol (LDL-C) and a decrease in high-density lipoprotein cholesterol (HDL-C) in streptozotocin-induced diabetic 
rats. Treatment of diabetic rats with PPE over a period of a month returned these levels close to control levels. CONCLUSION: 
These results suggest that PPE has hypolipidemic effects in streptozotocin-induced diabetic rats. 
KEYWORDS: P. pastinacifolium, Lipoproteins, Cholesterol, Hypercholesterolemia.
INTRODUCTION
The number of people with diabetes mellitus (DM) 
worldwide is rapidly increasing. There are currently 
more than 170 million people with diagnosed DM, and 
that number has been predicted to rise to more than 360 
million by 2030.1 In Iran, 7.7% of adults aged 25 to 64 
(approximately 2 million people) have been diagnosed 
with DM, and 16.8% of them (about 4.4 million) have 
impaired fasting glucose.2 DM is an endocrine disorder, 
and its complications are a major cause of disability and 
hospitalization, posing a significant financial burden. 
Dyslipidemia [elevated plasma levels of total cholesterol 
(TC), low-density lipoprotein-cholesterol (LDL-C) and 
triglycerides (TG) and a low concentration of high-
density lipoprotein-cholesterol (HDL-C)] is one of the 
most common complications of DM. It plays a significant 
role in the development of premature atherosclerosis, 
coronary insufficiency and myocardial infarction.3 Lipid 
profile abnormalities in diabetes are mediated through 
derangements in a variety of regulatory processes, especially 
insulin deficiency, thereby rendering diabetic patients more 
prone to hypercholesterolemia and hypertriglyceridemia.4 
Treatment of hyperlipidemia in diabetes involves improving 
glycemic control, getting exercise and using lipid-lowering 
diet and drugs.5 At present, dyslipidemia is most commonly 
treated with lipid-lowering drugs, some of which are associated 
with serious adverse side effects. Thus, the effects of dietary 
components on plasma lipid metabolism have recently received 
considerable attention, highlighting the importance of natural 
products as lipid metabolism regulators.6
Many medicinal plants have been found to be useful 
to successfully manage hyperlipidemia; these include 
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Dracocephalum kotschyi,7 Allium porrum,8 purslane,9 Eclipta 
prostrata,10 Scoparia dulcis,11 Trigonella foenum-graecum 
and red yeast rice.12 However, only a limited amount of 
clinical research exists to support their efficacy. 
Peucedanum pastinacifolium Boiss & Hausskn. is a 
plant belonging to the Apiaceae family, commonly known 
as “Alafe-Tofangchi”. The plant is eaten by people in 
the center and western regions of Iran, and it is believed 
to be useful as an antihyperlipedimic plant. A survey of 
the literature revealed no pharmacological studies of this 
plant. Some species of Peucedanum have been used as 
anti-inflammatory, analgesic and diuretic compounds 
in Europe,13 and some members of the family have 
antispasmodic,14 antihypertension,15 antihypeglycemic,16 
antitumor, antibacterial17 and antiplatelet aggregation 
activities.18 The most important chemical constituents of the 
genus Peucedanum are furanocoumarines, which have been 
isolated from several species.14,18-20
We previously demonstrated the hypolipidemic activity 
of the P. pastinacifolium plant in cholesterol-fed rats.21 
There are several reports that hyperglycemia is accompanied 
by increases in serum TC and TG levels in streptozotocin 
(STZ)-induced DM.22, 23 In the present study, we investigated 
the hypolipidemic effect of a P. pastinacifolium extract in 
STZ-induced diabetic rats. 
MATERIALS AND METHODS 
Plant material and extraction: Wild samples of P. 
pastinacifolium were collected from the Soffeh Mountains 
(1500 m) near Isfahan, Iran, in June 2007 and identified by 
the Botany Department of Isfahan University. A voucher 
specimen of the plant was deposited in the herbarium of the 
Faculty of Pharmacy and Pharmaceutical Sciences, Isfahan 
University of Medical Sciences, Isfahan, Iran (No. 1146). 
The aerial parts of plants were air dried and extracted at 
room temperature with a 70:30 ratio of ethanol:water. The 
hydroalcoholic extract was concentrated in vacuo, resulting 
in a crude extract.
Animals and experimental induction of diabetes: Adult 
male Wistar rats weighing approximately 200-250 g (obtained 
from the central animal house of the Tehran Pasteur Institute, 
Tehran, Iran) were housed in an air-conditioned room under a 
12-h light-dark cycle. The animals were allowed free access 
to tap water and standard laboratory rat food. All experimental 
procedures involving animals were approved by the Animal 
Research Ethics Committee of Isfahan University of Medical 
Sciences, Isfahan, Iran.
Diabetes mellitus was artificially induced by a single 
intraperitoneal (i.p.) injection of a freshly prepared STZ 
solution (Sigma, St. Louis, MO, USA) dissolved in 0.1 M 
citrate buffer, pH 4.5, at a dose of 60 mg/kg Body Weight 
(BW) to overnight-fasted rats.24 Control rats received an 
i.p. injection of citrate buffer alone. At three days post-
administration, rats with stabilized diabetes, as indicated by 
a fasting blood glucose level of more than 250 mg/dl, were 
selected for the study. Treatment was started on the fourth 
day after STZ administration and continued for 30 days.
Treatment protocol: The care and handling of rats were 
in accordance with the internationally accepted standard 
guidelines for use of animals, and the protocol was approved 
by our institutional committee on animal care. Normal and 
STZ-diabetic rats were randomly assigned to seven groups 
of six as follows:
Group I. Control rats receiving citrate buffer
Group II. Diabetic control rats
Groups III – V. Control rats orally treated with different 
doses of plant extract (125, 250, 500 mg/kg BW) in aqueous 
solution for 30 days.
Group VI. Diabetic rats fed with glibenclamide (5 mg/kg 
BW) in aqueous solution for 30 days.
Groups VII – IX. Diabetic rats orally treated with 
different doses of plant extract (125, 250, 500 mg/kg BW) 
in aqueous solution for 30 days.
At the end of the experimental period, the rats were 
anesthetized and killed by cervical dislocation. Blood 
samples were collected and the serum was separated by 
centrifugation (2000 g, 20 min, and 4°C) and submitted to 
biochemical analysis. The serum concentrations of glucose, 
TC, TG, LDL-C and HDL-C were determined with the 
use of commercially available enzyme kits (Pars Azmoon, 
Tehran, Iran). The atherogenic index [total cholesterol – 
HDL-C)/ HDL-C] was calculated.
Statistical analysis: The results are presented as mean 
± SD. Statistical analysis of the data was performed using 
an unpaired t-test and analysis of variance (ANOVA) with 
SPSS/11.5 software. Significant differences are indicated by 
p-values of less than 0.05. 
RESULTS
The serum lipid profiles of the control (group I) and 
STZ-induced diabetic rats (group II) are shown in Table 1. 
A significant (P < 0.05) increase in the levels of serum total 
cholesterol, triglyceride and LDL-C were observed in the 
diabetic rats, whereas the HDL-C level was markedly (P < 
0.05) decreased compared to normal control rats (Table 1). 
Table 2 shows the serum lipid profiles of the untreated 
control group (group I) and control groups treated with 
different doses of PPE (groups III-V). The treatment of 
control rats with PPE did not significantly affect any of the 
evaluated parameters (Table 2). 
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Diabetic rats treated with PPE (group IX) or glibenclamide 
(group VI) for 30 days had significantly reduced serum total 
cholesterol, triglyceride and LDL-C levels, whereas the 
HDL-C level was significantly increased compared to control 
diabetic rats (group II). Drug treatment restored these values 
to near control group levels (Table 3). Finally, the atherogenic 
index in groups treated with PPE (groups IX) or glibenclamide 
(group VI) were significantly decreased compared with the 
diabetic control group (group II). The treated animals had 
values similar to the normal levels seen in the control group 
(Table 4). The body weights and blood glucose levels at the 
initiation and end of the study period in normal and diabetic 
control groups are shown in Table 5.
DISCUSSION
DM is associated with profound alterations in the serum 
lipid and lipoprotein profiles and with an increased risk of 
coronary heart disease.5 Lowering serum lipid levels through 
dietary changes or drug therapy is associated with a decrease 
in the risk of vascular disease and related complications.25
Table 1 - Comparison of serum lipid profiles in normal and STZ-induced diabetic rats.
Group Total cholesterol (mg/dl) Triglyceride (mg/dl) LDL-C (mg/dl) HDL-C (mg/dl)
Normal  97 ± 10 53 ± 13 48 ± 9 38 ± 4
Diabetic  128* ± 15 87* ± 12 89* ± 19 21* ± 5
Values are the mean ± SD (n=6). * Represents a significant difference from the normal control group at P<0.05. LDL-C: Low-Density Lipoprotein-Cholesterol, 
HDL-C: High-Density Lipoprotein-Cholesterol, STZ: Streptozotocin
Table 2 - Comparison of serum lipid profiles in normal and PPE-treated normal rats.
Groups TC (% of control) TG (% of control) LDL-C (% of control) HDL-C (% of control)
Normal control 100 100 100 100
Treated groups
  125 mg/kg B.W. PPE 89 ± 7 93 ± 8 102 ± 10 97 ± 8
  250 mg/kg B.W. PPE 99 ± 6  101 ± 9 98 ± 9 90 ± 9
  500 mg/kg B.W. PPE 98 ± 7 94 ± 7 102 ± 9 92 ± 8
  5 mg/kg B.W. Glybenclamide 82 ± 9 80 ± 10 85 ± 10 84  ± 11
Values are the mean ± SD (n=6). * Represents significant difference from normal control group at P<0.05.  LDL-C: Low-Density Lipoprotein-Cholesterol, 
HDL-C: High-Density Lipoprotein-Cholesterol, TC: Total Cholesterol, TG: Triglycerides, PPE: Peucedanum pastinacifolium hydroalcoholic Extract
Table 3 - Effect of PPE on serum lipid profiles of STZ-induced diabetic rats.
Groups TC (% of control) TG (% of control) LDL-C (% of control) HDL-C (% of control)
Diabetic control 100 100 100 100
Treated groups
  125 mg/kg B.W. PPE 89 ± 7 83 ± 8 91 ± 7 90 ± 7
  250 mg/kg B.W. PPE 83 ± 8  86 ± 9 79 ± 9 98 ± 9
  500 mg/kg B.W. PPE 70* ± 6 79* ± 7 40* ± 6 190* ± 10
  5 mg/kg B.W. Glybenclamide 63* ± 6 52* ± 6 38* ± 6 186*  ± 9
Values are the mean ± SD (n=6). * Represents significant difference from diabetic control group at P<0.05.  LDL-C: Low-Density Lipoprotein-Cholesterol, 
HDL-C: High-Density Lipoprotein-Cholesterol, TC: Total Cholesterol, TG: Triglycerides, PPE: Peucedanum pastinacifolium hydroalcoholic Extract, STZ: 
Streptozotocin
Table 4 - Effect of PPE on the atherogenic index of STZ-
induced diabetic rats. 
Groups Atherogenic Index
Normal control 1.56 ± 0.26
Diabetic control 5.36 ± 1.96  
Treated groups
  125 mg/kg B.W. PPE 5.29 ± 1.09
  250 mg/kg B.W. PPE 4.49 ± 2.10
  500 mg/kg B.W. PPE 1.26* ± 0.31
  20 mg/kg B.W. Glybenclamide 1.09* ± 0.24
Values are the mean ± SD (n=6). * Represents significant difference from 
the diabetic control group at P<0.05.  PPE: Peucedanum pastinacifolium 
hydroalcoholic Extract, STZ: Streptozotocin
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Many herbs and plant products have been shown to have 
hypolipidemic properties7-12, and the hypolipidemic activity 
of PPE in hypercholesterolemic rats has been previously 
reported by the authors.21
In the present study, the ability of PPE to partially 
reverse the hyperlipideimia of STZ-induced diabetic rats is 
confirmed. Induction of diabetes in rats by administration of 
STZ led to the development of dyslipidemia. In our study, 
a marked increase in the lipid content of serum was found 
in STZ-induced diabetic rats (Table 1). The increase in the 
total serum cholesterol, triglyceride and LDL-C levels in 
the diabetic rats is mainly due to increased mobilization of 
free fatty acids from peripheral deposits, as insulin inhibits 
the hormone-sensitive lipase. The increase in the serum 
LDL-C level may also result from glycosylation of the lysyl 
residues of apoprotein B, which leads to a decrease in LDL 
metabolism due to a decrease in the affinity of LDL for its 
receptors. Our results show that the serum HDL-C level 
decreased in STZ-induced diabetic rats (Table 1). A number 
of observations indicate that the plasma HDL-C level is low 
in untreated diabetics .26 The hypolipidemic potency of PPE 
following daily administration indicated that it effectively 
reduces serum TC, TG and LDL-C levels and increases the 
serum HDL-C level in diabetic rats. Importantly, it had no 
effect on serum lipid profiles in normal rats (Tables 2 and 3).
The mechanism(s) of the hypolipidemic actions of PPE 
are not known; however, they could be mediated by control 
of tissue metabolism and improved insulin secretion and 
action because insulin lowers lipid levels and normalizes 
lipids in STZ-induced diabetic rats.27
The increase in the HDL-C level achieved by PPE 
significantly decreased the treated rats’ atherogenic index 
(Table 4). The HDL level inversely correlates with the risk of 
atherosclerotic cardiovascular disease. HDLs protect against 
or reverse atherosclerosis by their ability to serve as acceptor 
particles for macrophage cholesterol efflux, prevention of 
endothelial dysfunction and maintenance of endothelial 
integrity.28, 29 Thus, PPE has the potential to prevent the 
formation of atherosclerosis and coronary heart disease, 
which are secondary diabetic complications of severe DM.
In conclusion, alterations in lipid profiles were restored 
to near normal levels by PPE treatment of rats with 
experimentally induced diabetes. Several authors reported 
that secondary metabolites, such as furanocoumarines, 
saponins, flavonoids, phenolic compounds, and triterpenoids, 
have hypolipidemic activity.30-32 Hence, the hypolipidemic 
and anti-atherogenic properties of PPE may be due to 
different types of active secondary metabolites, each with 
a single or diverse range of biological activities. Further 
biochemical and pharmacological investigations are in 
progress to isolate and identify the active compounds in P. 
pastinacifolium.
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Table 5 - Changes in body weight and blood glucose in normal and 
diabetic control animals.  
Groups B.W (gr) Glucose (mg/dl)
1st day 30th day 1st day 30th day
Normal 
control 
208 ± 20 285 ± 30 97 ± 25 118 ± 20
Diabetic 
control
220 ± 18 160 ± 25 398 ± 89 333 ± 52
Values are the mean ± SD (n=6). B.W: Body Weight
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